Hims & Hers Health (NYSE:HIMS) Stock Price Down 6.3% – What’s Next?

Hims & Hers Health, Inc. (NYSE:HIMS) was down 6.3% during mid-day trading on Friday . The company traded as low as $26.70 and last traded at $27.0610. Approximately 3,162,114 shares changed hands during mid-day trading, a decline of 90% from the average daily volume of 30,509,105 shares. The stock had previously closed at $28.87.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on HIMS shares. Bank of America cut their price objective on shares of Hims & Hers Health from $28.00 to $25.00 and set a “neutral” rating for the company in a report on Tuesday, May 26th. Citigroup boosted their target price on shares of Hims & Hers Health from $24.00 to $28.00 and gave the company a “neutral” rating in a research report on Tuesday, May 12th. Evercore set a $24.00 target price on shares of Hims & Hers Health in a research report on Tuesday, February 24th. JPMorgan Chase & Co. dropped their target price on shares of Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating for the company in a research report on Tuesday, May 12th. Finally, Canaccord Genuity Group set a $32.00 target price on shares of Hims & Hers Health in a research report on Tuesday, May 12th. Four research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $28.70.

Hims & Hers Health Stock Down 7.0%

The firm’s 50-day moving average price is $25.41 and its 200 day moving average price is $26.83. The company has a market capitalization of $6.21 billion, a price-to-earnings ratio of -298.33, a PEG ratio of 50.32 and a beta of 2.37. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of 2.18.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The company had revenue of $608.10 million for the quarter, compared to analyst estimates of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.Hims & Hers Health’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.20 earnings per share. On average, sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.04 EPS for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 36,922 shares of the company’s stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $25.90, for a total transaction of $956,279.80. Following the completion of the transaction, the chief financial officer directly owned 281,867 shares in the company, valued at $7,300,355.30. This represents a 11.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Soleil Boughton sold 9,463 shares of the company’s stock in a transaction that occurred on Monday, April 20th. The stock was sold at an average price of $30.00, for a total transaction of $283,890.00. Following the transaction, the insider owned 299,368 shares of the company’s stock, valued at approximately $8,981,040. This represents a 3.06% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 212,807 shares of company stock worth $5,473,644 over the last 90 days. 11.76% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Hims & Hers Health

A number of institutional investors have recently added to or reduced their stakes in HIMS. Farallon Capital Management LLC increased its position in Hims & Hers Health by 30.8% in the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after acquiring an additional 2,533,271 shares during the period. BIT Capital GmbH increased its position in Hims & Hers Health by 73.8% in the 3rd quarter. BIT Capital GmbH now owns 2,210,384 shares of the company’s stock valued at $125,373,000 after acquiring an additional 938,728 shares during the period. SG Americas Securities LLC increased its position in Hims & Hers Health by 25.6% in the 4th quarter. SG Americas Securities LLC now owns 371,553 shares of the company’s stock valued at $12,064,000 after acquiring an additional 75,679 shares during the period. Vanguard Group Inc. increased its position in Hims & Hers Health by 7.2% in the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock valued at $679,456,000 after acquiring an additional 1,407,651 shares during the period. Finally, CI Investments Inc. increased its position in Hims & Hers Health by 6,659.7% in the 3rd quarter. CI Investments Inc. now owns 206,510 shares of the company’s stock valued at $11,713,000 after acquiring an additional 203,455 shares during the period. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.